CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Total	Public Offering	Private Placement	Equity Line Of Credit	Series F Preferred Stock	Series F Preferred Stock Public Offering	Series E Preferred Stock	Preferred Stock	Preferred Stock Series F Preferred Stock	Preferred Stock Series F Preferred Stock Public Offering	Preferred Stock Series E Preferred Stock	Common Stock	Common Stock Public Offering	Common Stock Private Placement	Common Stock Equity Line Of Credit	Common Stock Series F Preferred Stock	Common Stock Series E Preferred Stock	Additional Paid-In Capital	Additional Paid-In Capital Public Offering	Additional Paid-In Capital Private Placement	Additional Paid-In Capital Equity Line Of Credit	Additional Paid-In Capital Series F Preferred Stock	Additional Paid-In Capital Series F Preferred Stock Public Offering	Additional Paid-In Capital Series E Preferred Stock	Accumulated Other Comprehensive Loss	Accumulated Deficit
Balance (in shares) at Dec. 31, 2021								7				316,599
Balance at Dec. 31, 2021	$ 14,579,048							$ 0				$ 3,166						$ 135,541,662							$ (86,431)	$ (120,879,349)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-Based Compensation	462,450																	462,450
Issuance of Panoptes Holdback Shares (in shares)												10,087
Issuance of Panoptes Holdback Shares	0											$ 100						(100)
Issuance of Stock (in shares)											1,280		592,392
Issuance of Stock		$ 2,462,838					$ 665,191				$ 13		$ 5,924						$ 2,456,914					$ 665,178
Issuance of shares of common stock from warrant exercises (in shares)												65,000
Issuance of Shares of Common Stock from Warrant Exercises	520,000											$ 650						519,350
Conversion of Preferred Stock into Common Stock (in shares)											(1,280)						160,000
Conversion of Preferred Stock into Common Stock							$ 0				$ (13)						$ 1,600							$ (1,587)
Reclassification of Warrant Liability	3,674,791																	3,674,791
Cancellation of Reverse Stock Split Fractional Shares (in shares)												(2,215)
Cancellation of Reverse Stock Split Fractional Shares	(15,629)																	(15,629)
Issuance of Common Stock from Warrant Inducement, Net of Issuance Costs of $381,360 (in shares)												654,609
Issuance of Common Stock from Warrant Inducement, Net of Issuance Costs of $381,360	2,738,831											$ 6,546						2,732,285
Foreign Currency Translation Adjustment	(96,310)																								(96,310)
Net Loss	(13,583,610)																									(13,583,610)
Balance at Dec. 31, 2022	11,407,600							$ 0				$ 17,986						146,035,314							(182,741)	(134,462,959)
Balance (in shares) at Dec. 31, 2022								7				1,796,472
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-Based Compensation	754,944																	754,944
Issuance of Stock (in shares)										3,908			2,197,628	52,798	125,000
Issuance of Stock		$ 1,018,455	$ 115,715	$ 442,310		$ 1,646,289				$ 39			$ 21,976	$ 528	$ 1,250				$ 996,479	$ 115,187	$ 441,060		$ 1,646,250
Issuance of Class C and D warrants from Public Offering, Net of Offering Costs of $381,877	2,931,218																	2,931,218
Issuance of shares of common stock from warrant exercises (in shares)												66,400
Issuance of Shares of Common Stock from Warrant Exercises	307,079											$ 664						306,415
Conversion of Preferred Stock into Common Stock (in shares)									(3,488)							3,170,592
Conversion of Preferred Stock into Common Stock					$ 0				$ (35)							$ 31,706						$ (31,671)
Issuance of Common Stock from Restricted Stock Awards (in shares)												296,750
Issuance of Common Stock from Restricted Stock Awards	0											$ 2,968						(2,968)
Foreign Currency Translation Adjustment	(60)																								(60)
Net Loss	(12,513,896)																									(12,513,896)
Balance at Dec. 31, 2023	$ 6,109,654							$ 4				$ 77,078						$ 153,192,228							$ (182,801)	$ (146,976,855)
Balance (in shares) at Dec. 31, 2023								427				7,705,640